3.90 USD
▲+0.13+2.09%
盘后 3.82 0.00%
2026-08-03
市值
$247.90M
市盈率
—
EPS
-1.11
股息率
—
52 周区间
1.29 – 5.08
成交量
875.96K
Beta
1.22
目标价
6.75
52W 低 1.2952W 高 5.08
价格走势
公司简介
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MG...